Novus Comms

In this insightful video featuring Bob Munro and Poolbeg’s Principal Scientist, Liam Tremble, the conversation explores the vital role of patient advocacy. Bob shares his personal journey into advocacy, reflecting on what inspired him to get involved and the projects he is currently championing. Through his advocacy work, Bob aims to highlight the positive impact of treatment outcomes, including his own remarkable journey to complete remission after 11 years. His dedication to research, unwavering drive, and continued support within the cancer community are truly commendable, and we congratulate him on the meaningful difference he is making. At Poolbeg Pharma plc, we share this commitment to improving patient outcomes and patient access through the development of POLB 001. Through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS), we hope that POLB 001 can make cancer immunotherapies safer and more widely available and accessible to patients worldwide. Learn more: poolbegpharma.com/pipeline/polb-… #POLB #CRS #CancerTreatment #CancerImmunotherapy #PatientAdvocacy #Myleoma #Cancer #Oncology

Our latest investor presentation is now available to download on our website📢 The presentation outlines the recent acquisition of a critical infrastructure services platform, key investment highlights, overview of @Earthmill, WEP, Silverford and Anemos Analytics, including repowering - a strategic growth opportunity. 🔗 Visit our website to access the full presentation and learn more about our progress and future plans: europeangreentransition.com/investors/pres… #Investors #InvestorUpdate #GrowthStrategy #EnergyTransition #Infrastructure

In case you missed yesterday's @InvestorMeetCo presentation featuring our Co-founder & Chair Cathal Friel, CFO Jack Kelly and Managing Director Dave Broadbank, then you can catch up by clicking on the link below: youtube.com/watch?v=nVtNbk… #EGT #Investors #AIM #InvestorPresentation #WindTurbine #IMC #InvestorMeetCo

In infectious disease and immunology research, choosing the right laboratory partner is critical to success. At hVIVO, our purpose-built laboratories deliver specialist, GCLP/GxP-compliant solutions designed to de-risk development, accelerate timelines and generate high-quality, reproducible data you can trust. ✔ Integrated expertise across molecular biology, virology, immunology and bacteriology ✔ Seamless lab–clinic–participant co-location to streamline study execution ✔ Bespoke assay development tailored to your programme ✔ End-to-end support from early discovery through to clinical trials ✔ Ongoing investment in advanced technologies and platforms ✔ Strong regulatory, ethical and quality frameworks Our experienced, collaborative teams work in a flat, peer-to-peer structure—keeping your programme moving efficiently while we manage the operational complexity behind the scenes. 📄 Learn more in our latest factsheet: hvivo.com/articles-and-r… #hVIVO #DrugDevelopment #InfectiousDisease #Immunology #LaboratoryScience #Biotech #ClinicalResearch #TranslationalResearch

A reminder 🔔that #EGT is hosting an investor presentation this evening. 🟢 Wednesday 18 March at 5pm GMT 🟢 Virtual presentation 🟢 Open to all existing & potential #shareholders Questions can be submitted in advance via @InvestorMeetCo dashboard. Register to attend: investormeetcompany.com/european-green… #InvestorPresentation #VirtualPresentation #IMC #InvestorMeetCo #AIM #CompanyPresentation #investors

Reminder🔔 that our Executive Chair, Cathal Friel, will be speaking during the Mini TED Talks session at the upcoming @PharmaMgrsInst The Pharmaceutical Managers Institute of Ireland Annual Pharma Summit. 📍 Croke Park Conference Centre 📅 26 March 2026 ⏱️ 8:30 am – 4:00 pm 🔗 Learn more and register: thepmi.com/events/pharma-… #POLB #PMI #Pharma #Healthcare #Leadership #Conference #Dublin

We were recently featured in the @Independent_ie following our latest fundraise and strategic acquisitions in the wind energy sector. We successfully raised £7.5m in a placing that was significantly oversubscribed, demonstrating strong investor confidence in our strategy to build a leading platform focused on critical infrastructure services supporting the energy transition. The proceeds will support the integration and growth of the wind turbine operations and maintenance businesses we recently acquired Earthmill Maintenance Ltd, WEP (Wind Energy Partnership), Silverford Engineering and Anemos Analytics. Together, these businesses service more than 900 onshore wind turbines across Ireland and the UK and generated £14.7m in revenue in 2025. These platforms provide a strong operational foundation as we scale the business and pursue opportunities in distributed wind generation, enabling farms and businesses to produce power close to where it is consumed while locking in predictable energy costs. We also see a significant opportunity emerging in the repowering of ageing wind turbines following the lifting of the UK’s onshore wind ban, with Earthmill already signing agreements with 53 clients in this area. With our highly experienced team and clear visibility on both near- and long-term revenue opportunities, we remain focused on scaling the platform and delivering on our medium-term target of £50m in revenue with double-digit EBITDA margins. Read full article here: m.independent.ie/business/catha… #EGT #EnergyTransition #WindEnergy #Renewables #Infrastructure #EGT

⏳ Last chance to register! Our live panel, Fast‑Tracking First‑In‑Human: A Startup-Focused Guide to IND Readiness, is happening tomorrow: 🗓 March 18th, 2026 🕒 8am PDT | 11am EDT | 3pm GMT | 4pm CET Join us for actionable insights on: • Aligning IND workstreams • Avoiding early‑stage development pitfalls • Structuring smart FIH study designs • Reducing risk while accelerating timelines 👉 Register before we go live - use the link in the comments below: discover.pharmaignite.com/startup-focuse… #HVO #hVIVO #Biotech #Pharma #ClinicalDevelopment #FIH #DrugDevelopment

Our Principal Scientist Liam Tremble speaks with Bob Munro, a Multiple Myeloma patient currently in remission. Bob speaks on his diagnosis, treatment journey, and patient advocacy. 🩺Bob’s cancer diagnosis 🏥11 years of continuous treatment 💊Cancer immunotherapy treatment leading to remission 👉Severe debilitating side effects 💪Patient advocacy & personal goals In this conversation, Bob reflects on the challenges he faced throughout his treatment and the resilience required to keep going. He also discusses why patient voices are critical in shaping research, care, and support for others living with Multiple Myeloma. Learn more about POLB 001: poolbegpharma.com/pipeline/polb-… #POLB #CRS #CancerTreatment #CancerImmunotherapy

EGT's Co-founder & Chair Cathal Friel & Managing Director of the O&M Business Dave Broadbank spoke with Stephen Gunnion from @proactive_x. ✅ Result of conditional fundraise of £7.5m 🔍 Acquisition of onshore wind turbine operating, maintenance, repairs and remote monitoring business 🚀 Growing importance of energy independence & repowering opportunity 🎯 Group's medium term target of £50m revenue & double digit EBITDA margin Watch the full interview here: youtube.com/watch?v=FlP10A… #EGT #AIM #Fundraise #WindEnergy #WindTurbine #Services #Finance #Acquisition

Our CEO Jeremy Skillington, PhD will be joining a panel this year's @LSXLeaders World Congress Europe in Lisbon, Portugal. 📍Lisbon Congress Centre 🗓️ 25-26 March 2026 🗣️Panel: Unlocking opportunities in Public Markets: Strategies for Biotech Success Jeremy will take to the stage on Thursday 26 March at 11:10 alongside Werner Lanthaler of Wlanholding, Ari-Pekka Laitsaari from the European Investment Bank (EIB) and moderated by John Rudy of Mintz. If you are attending and would like to connect with Jeremy, email partnering@poolbegpharma.com. Learn more about the panel here: #capital-markets-investment-strategies_unlocking-opportunities-in-public-markets-strategies-for-biotech-success" target="_blank" rel="nofollow noopener">informaconnect.com/lsx-world-cong… #POLB #PanelDiscussion #LSXLeaders #LSXCongress #Lisbon #AIM #CapitalMarkets #Biotech #Investors

Our leadership team, Co-founder & Chair Cathal Friel, CFO Jack Kelly and Managing Director of the O&M Business Dave Broadbank will provide a live Investor Meet Company presentation. 🕰️ Wednesday 18 March | 5pm GMT 💻 Virtual presentation ✅ Open to all existing and potential shareholders Learn more and register to attend: londonstockexchange.com/news-article/E… #EGT #AIM #London #InvestorPresentation #CompanyPresentation #WindTurbine #WindPower #UK

Infectious disease and vaccine research is evolving rapidly and clinical trial laboratories are under increasing pressure to generate more insight from fewer samples. At hVIVO, we’re excited to share how next-generation droplet digital PCR technology is helping transform molecular analysis in infectious disease research and clinical trials. In our latest blog, we explore: 🔬How ddPCR platforms are improving sensitivity and precision alongside NGS 🧬Why extracting more value from limited biological samples is critical in early-phase studies ⚡How high-resolution molecular data can accelerate vaccine and drug development We also highlight an important milestone: hVIVO becoming the first global clinical trial laboratory to adopt the Bio-Rad QX700S ddPCR platform, reinforcing our commitment to advancing infectious and immunology research. 👉 Read the full blog to learn how next-generation droplet digital PCR is shaping the future of infectious disease studies: hvivo.com/articles-and-r… #HVO #hVIVO #InfectiousDisease #ClinicalTrials #VaccineResearch #DigitalPCR #MolecularDiagnostics #Biotech #DrugDevelopment

#EGT European Green Transition PLC - Investor Presentation via Investor Meet Company - Will host a live presentation on Investor Meet Company on 18 March 2026 at 17:00 GMT. - The event is open to existing and potential shareholders. novuscomms.com/2026/03/16/egt…

Yesterday we announced the appointment of Dr Adrian Kilcoyne to our Scientific Advisory Board. Check out what he had to say about joining! Dr Kilcoyne brings a wealth of experience in oncology and cell therapy drug development, combined with deep clinical insight and regulatory expertise which will be invaluable to us as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems. #POLB #SAB #ScientificAdvisoryBoard #Oncology #Cancer #BoardUpdate

#EGT European Green Transition PLC - Notice of General Meeting & Posting of Circular - The General Meeting will take place at the offices of DAC Beachcroft LLP at The Walbrook Building, 25 Walbrook, London EC4N 8AF on 30 March 2026 at 9:30 a.m. novuscomms.com/2026/03/13/egt…

Most IND timelines slip long before regulators see the package. The root cause? Early decisions made in silos. Join our live webinar on Wednesday, March 18th, 2026 🕒 8am PDT | 11am EDT | 3pm GMT | 4pm CET Our panel of experts will break down how startups can: • Integrate non‑clinical, CMC & regulatory strategy early • Avoid rework, misalignment & delays • Build a realistic, de‑risked path to FIH • Communicate effectively with investors 👉 Save your seat using the link in the comments below: discover.pharmaignite.com/startup-focuse… #IND #FirstInHuman #RegulatoryStrategy #CMC #BiotechStartups

EGT has conditionally raised gross proceeds of £7.5 million via a placing and subscription, which was upsized from c.£5 million and was significantly oversubscribed. “We believe the quality and scale of interest, including from institutions, strongly validates the transaction we completed in recent weeks, acquiring an established, EBITDA profitable onshore wind turbine operations, maintenance, repair, and remote monitoring business. With £7.5 million conditionally raised, EGT will be debt free and strongly positioned for its next phase of growth. We have clear visibility over both near- and long-term revenues and an experienced team in place to execute our strategy, scale the business rapidly and achieve our medium-term target of £50m revenue and double-digit EBITDA margins. Our focus remains on executing our strategy and creating sustainable long-term value for our shareholders.” Cathal Friel, Executive Chair See full announcement: londonstockexchange.com/news-article/E… #EGT #Fundraise #London #LSEG #Placing #Subscription #EuropeanGreenTransition #Funds

To enhance our expertise in the Cytokine Release Syndrome space we have appointed Dr Adrian Kilcoyne to our Scientific Advisory Board. Dr Kilcoyne bring over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome. Adrian’s wealth of experience will provide further support to our established team of experts as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems. Learn more about Dr Kilcoyne’s experience and read the full announcement here: londonstockexchange.com/news-article/P… #POLB #SAB #ScientificAdvisory #BoardMember #AIM #Cancer #Oncology #ScientificExpert

A recent @Citeline In Vivo article gathered views from industry leaders during British Science Week on what’s holding the UK biotech sector back and how it can compete globally. Our CEO Jeremy Skillington highlighted the importance of expanding risk capital in the ecosystem. With university spin-outs emerging rapidly, funding remains a key bottleneck. He also stressed that with countries like China executing clinical development quickly and at scale, the UK must move with similar urgency to remain competitive. Read the full article here: insights.citeline.com/in-vivo/leader… ✍️@Stephen__Adams #BritishScienceWeek #POLB #UKLifeSciences #Biotech #ScienceWeek #Industry